Journal of Peking University (Health Sciences) ›› 2022, Vol. 54 ›› Issue (5): 884-895. doi: 10.19723/j.issn.1671-167X.2022.05.016
Previous Articles Next Articles
Xiao-jing CHENG1,Dong JIANG2,Lian-hai ZHANG1,Jiang-hua WANG2,Ya-zhen LI2,Jia-hui ZHAI2,Bao-qi YAN2,Lu-lu ZHANG2,Xing-wang XIE2,*(),Zi-yu LI1,*(),Jia-fu JI1,*()
CLC Number:
1 | Bos JL . Ras oncogenes in human cancer: A review[J]. Cancer Res, 1989, 49 (17): 4682- 4689. |
2 |
Singh H , Longo DL , Chabner BA . Improving prospects for targeting RAS[J]. J Clin Oncol, 2015, 33 (31): 3650- 3659.
doi: 10.1200/JCO.2015.62.1052 |
3 | Hobbs GA , Der CJ , Rossman KL . RAS isoforms and mutations in cancer at a glance[J]. J Cell Sci, 2016, 129 (7): 1287- 1292. |
4 |
Windon AL , Loaiza-Bonilla A , Jensen CE , et al. A KRAS wild type mutational status confers a survival advantage in pancreatic ductal adenocarcinoma[J]. J Gastrointest Oncol, 2018, 9 (1): 1- 10.
doi: 10.21037/jgo.2017.10.14 |
5 |
Shin SH , Kim SC , Hong SM , et al. Genetic alterations of K-ras, p53, c-erbB-2, and DPC4 in pancreatic ductal adenocarcinoma and their correlation with patient survival[J]. Pancreas, 2013, 42 (2): 216- 222.
doi: 10.1097/MPA.0b013e31825b6ab0 |
6 |
Bournet B , Muscari F , Buscail C , et al. KRAS G12D mutation subtype is a prognostic factor for advanced pancreatic adenocarcinoma[J]. Clin Transl Gastroenterol, 2016, 7 (3): e157.
doi: 10.1038/ctg.2016.18 |
7 |
Haas M , Ormanns S , Baechmann S , et al. Extended RAS analysis and correlation with overall survival in advanced pancreatic cancer[J]. Br J Cancer, 2017, 116 (11): 1462- 1469.
doi: 10.1038/bjc.2017.115 |
8 |
Marabese M , Ganzinelli M , Garassino MC , et al. KRAS mutations affect prognosis of non-small-cell lung cancer patients treated with first-line platinum containing chemotherapy[J]. Oncotarget, 2015, 6 (32): 34014- 34022.
doi: 10.18632/oncotarget.5607 |
9 |
Laghi L , Orbetegli O , Bianchi P , et al. Common occurrence of multiple KRAS mutations in pancreatic cancers with associated precursor lesions and in biliary cancers[J]. Oncogene, 2002, 21 (27): 4301- 4306.
doi: 10.1038/sj.onc.1205533 |
10 | Russo AL , Borger DR , Szymonifka J , et al. Mutational analysis and clinical correlation of metastatic colorectal cancer[J]. Can-cer, 2014, 120 (10): 1482- 1490. |
11 |
Tran E , Ahmadzadeh M , Lu YC , et al. Immunogenicity of soma-tic mutations in human gastrointestinal cancers[J]. Science, 2015, 350 (6266): 1387- 1390.
doi: 10.1126/science.aad1253 |
12 |
Chatani PD , Yang JC . Mutated RAS. Targeting the "untargetable" with T cells[J]. Clin Cancer Res, 2020, 26 (3): 537- 544.
doi: 10.1158/1078-0432.CCR-19-2138 |
13 |
Tran E , Robbins PF , Lu YC , et al. T-cell transfer therapy targeting mutant KRAS in cancer[J]. N Engl J Med, 2016, 375 (23): 2255- 2262.
doi: 10.1056/NEJMoa1609279 |
14 |
Leidner R , Sanjuan Silva N , Huang H , et al. Neoantigen T-cell receptor gene therapy in pancreatic cancer[J]. N Engl J Med, 2022, 386 (22): 2112- 2119.
doi: 10.1056/NEJMoa2119662 |
15 | Wang QJ , Yu Z , Griffith K , et al. Identification of T-cell receptors targeting KRAS-mutated human tumors[J]. Cancer Immunol Res, 2015, 4 (3): 204- 214. |
16 |
Sim MJW , Lu J , Spencer M , et al. High-affinity oligoclonal TCRs define effective adoptive T cell therapy targeting mutant KRAS-G12D[J]. Proc Natl Acad Sci USA, 2020, 117 (23): 12826- 12835.
doi: 10.1073/pnas.1921964117 |
17 |
Cohen CJ , Zhao Y , Zheng Z , et al. Enhanced antitumor activity of murine-human hybrid T-cell receptor (TCR) in human lymphocytes is associated with improved pairing and TCR/CD3 stability[J]. Cancer Res, 2006, 66 (17): 8878- 8886.
doi: 10.1158/0008-5472.CAN-06-1450 |
18 |
Morgan RA , Chinnasamy N , Abate-Daga D , et al. Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy[J]. J Immunother, 2013, 36 (2): 133- 151.
doi: 10.1097/CJI.0b013e3182829903 |
19 |
Linette GP , Stadtmauer EA , Maus MV , et al. Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma[J]. Blood, 2013, 122 (6): 863- 871.
doi: 10.1182/blood-2013-03-490565 |
20 | Cameron BJ , Gerry AB , Dukes J , et al. Identification of a Titin-derived HLA-A1-presented peptide as a cross-reactive target for engineered MAGE A3-directed T cells[J]. Sci Transl Med, 2013, 5 (197): 103- 126. |
21 |
Suchin EJ , Langmuir PB , Palmer E , et al. Quantifying the frequency of alloreactive T cells in vivo: New answers to an old question[J]. J Immunol, 2001, 166 (2): 973- 981.
doi: 10.4049/jimmunol.166.2.973 |
22 |
Li J , Li W , Huang K , et al. Chimeric antigen receptor T cell (CAR-T) immunotherapy for solid tumors: lessons learned and strategies for moving forward[J]. J Hematol Oncol, 2018, 11 (1): 22.
doi: 10.1186/s13045-018-0568-6 |
23 | Idorn M , Skadborg SK , Kellermann L , et al. Chemokine receptor engineering of T cells with CXCR2 improves homing towards subcutaneous human melanomas in xenograft mouse model[J]. Oncoimmunology, 2018, 7 (8): e1450715. |
24 |
Draper LM , Kwong ML , Gros A , et al. Targeting of HPV-16+ epithelial cancer cells by TCR gene engineered T cells directed against E6[J]. Clin Cancer Res, 2015, 21 (19): 4431- 4439.
doi: 10.1158/1078-0432.CCR-14-3341 |
25 |
Karapetis CS , Khambata-Ford S , Jonker DJ , et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer[J]. N Engl J Med, 2008, 359 (17): 1757- 1765.
doi: 10.1056/NEJMoa0804385 |
26 |
Moore AR , Rosenberg SC , McCormick F , et al. RAS-targeted therapies: Is the undruggable drugged?[J]. Nat Rev Drug Discov, 2020, 19 (8): 533- 552.
doi: 10.1038/s41573-020-0068-6 |
[1] | Li LIANG,Xin LI,Lin NONG,Ying DONG,Ji-xin ZHANG,Dong LI,Ting LI. Analysis of microsatellite instability in endometrial cancer: The significance of minimal microsatellite shift [J]. Journal of Peking University (Health Sciences), 2023, 55(2): 254-261. |
[2] | Jing YANG,Juan DU,Yu-xiang WANG,Cong-rong LIU. Activation of JAK/STAT in ovarian high-grade serous cancers and its prognostic significance [J]. Journal of Peking University (Health Sciences), 2023, 55(2): 270-275. |
[3] | Wei-hua HOU,Shu-jie SONG,Zhong-yue SHI,Mu-lan JIN. Clinicopathological features of Helicobacter pylori-negative early gastric cancer [J]. Journal of Peking University (Health Sciences), 2023, 55(2): 292-298. |
[4] | Fang CAO,Ming ZHONG,Cong-rong LIU. Uterine POLE mutant endometrioid carcinoma combined with human papilloma virus-associated cervical adenocarcinoma: A case report and literature review [J]. Journal of Peking University (Health Sciences), 2023, 55(2): 370-374. |
[5] | Yue WANG,Shuang ZHANG,Hong ZHANG,Li LIANG,Ling XU,Yuan-jia CHENG,Xue-ning DUAN,Yin-hua LIU,Ting LI. Clinicopathological features and prognosis of hormone receptor-positive/human epidermal growth factor receptor 2-negative breast cancer [J]. Journal of Peking University (Health Sciences), 2022, 54(5): 853-862. |
[6] | Li ZHANG,Ji-fang GONG,Hong-ming PAN,Yu-xian BAI,Tian-shu LIU,Ying CHENG,Ya-chi CHEN,Jia-ying HUANG,Ting-ting XU,Fei-jiao GE,Wan-ling HSU,Jane SHI,Xi-chun HU,Lin SHEN. Atezolizumab therapy in Chinese patients with locally advanced or metastatic solid tumors: An open-label, phase Ⅰ study [J]. Journal of Peking University (Health Sciences), 2022, 54(5): 971-980. |
[7] | Min QIU,Yan-yan LIAN,Min LU,Bin-shuai WANG,Xiao-jun TIAN,Jian LU,Cheng LIU,Shu-dong ZHANG,Min JIANG,Lu-lin MA. Treatment and prognosis of multiple primary malignant neoplasms complicated with renal cell carcinoma [J]. Journal of Peking University (Health Sciences), 2022, 54(4): 680-685. |
[8] | Zhe HAO,Shu-hua YUE,Li-qun ZHOU. Application of Raman-based technologies in the detection of urological tumors [J]. Journal of Peking University (Health Sciences), 2022, 54(4): 779-784. |
[9] | DING Ting-ting,ZENG Chu-xiong,HU Li-na,YU Ming-hua. Establishment of a prediction model for colorectal cancer immune cell infiltration based on the cancer genome atlas (TCGA) database [J]. Journal of Peking University (Health Sciences), 2022, 54(2): 203-208. |
[10] | LI Bing-yu,TANG Zu-nan,HU Lei-hao,ZHANG Wen-bo,YU Yao,YU Guang-yan,PENG Xin. Clinicopathologic analysis of micro and mini parotid gland tumors [J]. Journal of Peking University (Health Sciences), 2022, 54(2): 335-339. |
[11] | GU Yang-chun,LIU Ying,XIE Chao,CAO Bao-shan. Pituitary immune-related adverse events induced by programmed cell death protein 1 inhibitors in advanced lung cancer patients: A report of 3 cases [J]. Journal of Peking University (Health Sciences), 2022, 54(2): 369-375. |
[12] | NIU Zhan-yue,XUE Yan,ZHANG Jing,ZHANG He-jun,DING Shi-gang. Analysis of endoscopic and pathological features of gastric adenomatous polyps and risk factors for canceration [J]. Journal of Peking University (Health Sciences), 2021, 53(6): 1122-1127. |
[13] | YE Jian-fei,ZHAO Lei,WANG Guo-liang,HONG Kai,MA Lu-lin. Clinical analysis of testicular rhabdomyosarcoma [J]. Journal of Peking University (Health Sciences), 2021, 53(6): 1178-1182. |
[14] | KANG Wen-yu,WANG Lu,QIU Min,ZHANG Fan,GUO Wei,QIANG Ya-yong,TUO Peng-fei,ZONG You-long,LIU Lei-lei,WANG Shuai-shuai. Adrenal cavernous hemangioma: A case report and literature review [J]. Journal of Peking University (Health Sciences), 2021, 53(4): 808-810. |
[15] | LIN Guo-zhong, MA Chang-cheng, WANG Zhen-yu, XIE Jing-cheng, LIU Bin, CHEN Xiao-dong. Minimally invasive treatment of cervical1-2 epidural neurilemmoma [J]. Journal of Peking University (Health Sciences), 2021, 53(3): 586-589. |